Topoisomerase II inhibitor-induced apoptosis in thymocytes and lymphoma cells

Advances in Enzyme Regulation

Volumn 37, Issue , 1997, Pages 403-423

  Kizaki, Harutoshi ^a   Onishi, Yoshiaki ^a  

^a TOKYO DENTAL COLLEGE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1,2 BIS(3,5 DIOXOPIPERAZIN 1 YL)ETHANE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DNA FRAGMENT; DNA TOPOISOMERASE (ATP HYDROLYSING); DRUG DERIVATIVE; ENZYME INHIBITOR; ETOPOSIDE; GYRASE INHIBITOR; HETEROGENEOUS-NUCLEAR RIBONUCLEOPROTEINS; PIPERAZINE DERIVATIVE; RAZOXANE; RIBONUCLEOPROTEIN;

AMINO ACID SEQUENCE; ANIMAL; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CELL CULTURE; CELL CYCLE; CELL PROLIFERATION; CHEMISTRY; CONFERENCE PAPER; CONTROLLED STUDY; CYTOLOGY; CYTOTOXICITY; CYTOTOXICITY TEST; DNA DEGRADATION; DNA DETERMINATION; DNA SEQUENCE; DRUG EFFECT; DRUG MECHANISM; GENE EXPRESSION REGULATION; LYMPHOMA; LYMPHOMA CELL; MALE; METABOLISM; MOLECULAR GENETICS; MOUSE; MOUSE STRAIN; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOLOGY; PHYSIOLOGY; RNA SPLICING; T LYMPHOCYTE; THYMOCYTE; THYMUS;

AMINO ACID SEQUENCE; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BASE SEQUENCE; CELL CYCLE; CELLS, CULTURED; DNA FRAGMENTATION; DNA TOPOISOMERASES, TYPE II; ENZYME INHIBITORS; ETOPOSIDE; GENE EXPRESSION REGULATION; HETEROGENEOUS-NUCLEAR RIBONUCLEOPROTEIN GROUP A-B; HETEROGENEOUS-NUCLEAR RIBONUCLEOPROTEINS; LYMPHOMA; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; RAZOXANE; RIBONUCLEOPROTEINS; T-LYMPHOCYTES; THYMUS GLAND;

ANIMALIA;

EID: 0030756586     PISSN: 00652571     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0065-2571(96)00014-3     Document Type: Conference Paper

References (51)

1. 1. J. C. WANG, DNA topoisomerases, Annu. Rev. Biochem. 54, 665-697 (1985).
2. 2. H.-P. VOSBERG, DNA topoisomerases: enzymes that control DNA conformation, Curr. Top. Microbiol. Immunol. 114, 19-102 (1985).
3. 3. J. C. WANG, DNA topoisomerases, Annu. Rev. Biochem. 65, 635-692 (1996).
4. 4. W. G. NELSON, K. J. PIENTA, B. F. BARRACK and D. S. COFFEY, The role of the nuclear matrix in the organization and function of DNA, Annu. Rev. Biophys. Biophys. Chem. 15, 457-475 (1986).
5. 5. S.I. DWORETZKY, K.L. WRIGHT, E.G. FEY, S. PENMAN, J.B. LIAN, J.L. STEIN and G.S. STEIN, Sequence-specific DNA-binding proteins are components of a nuclear matrix-attachment site, Proc. Natl Acad Sci. USA 89, 4178-4182 (1992).
6. 6. S. V. RAZIN, I. I. GROMOVA and O. V. IAROVAIA, Specificity and functional significance of DNA interaction with the nuclear matrix: new approaches to clarify the old questions, Int. Rev. Cytol. 1628, 405-448 (1995).
7. 7. W. C. EARNSHAW, W. B. HALLIGAN, C. A. COOKE, M. M. HECK and L. F. LIU, Topoisomerase II is a structural component of mitotic chromosome scaffolds, J. Cell Biol. 100, 1706-1715 (1985).
8. 8. F. H. DRAKE, J. P. ZIMMERMAN, F. L. MCCABE, H. F. BARTUS, S. R. PER, D. M. SULLIVAN, W. E. ROSS, M. R. MATTERN, R. K. JOHNSON, S. T. CROOKE and C. K. MIRABELLI, Purification of topoisomerase II from amsacrine-resistant P388 leukemia cells: evidence for two forms of the enzyme, J. Biol. Chem. 262, 16739-16747 (1987).
9. 9. F. H. DRAKE, G. A. HOFMANN, H. F. BARTUS, M. R. MATTERN, S. T. CROOKE and C. K. MIRABELLI, Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II, Biochemistry 28, 8154-8160 (1989).
10. 10. M. K. DANKS, J. QIU, C. V. CATAPANO, C. A. SCHMIDT, W. T. BECK and D. J. FERNANDES, Subcellular distribution of the α and β topoisomerase II-DNA complexes stabilized by VM-26, Biochem. Pharmacol. 48, 1785-1795 (1994).
11. 11. N. ZINI, S. SANTI, A. OGNIBENE, A. BAVELLONI, L. M. NERI, A. VALMORI, E. MARIANI, C. NEGRI, G. C. B. ASTALDI-RICOTTI and N. M. MARALDI, Discrete localization of different topoisomerases in Hela and K562 cell nuclei and subnuclear fractions, Exptl Cell Res. 210, 336-348 (1994).
12. 12. K. DRLICA and R. J. FRANCO, Inhibitors of DNA topoisomerases, Biochemistry 27, 2253-2259 (1988).
13. 13. L. F. LIU, DNA topoisomerases poisons as antitumor drugs, Annu. Rev. Biochem. 58, 351-375 (1989).
14. 14. A. Y. CHEN and L. F. LIU, DNA topoisomerases: essential enzymes and lethal targets, Annu. Rev. Pharmacol. Toxicol. 34, 191-218 (1994).
15. 15. K. TANABE, Y. IKEGAMI, R. ISHIDATE and T. ANDOH, Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivatives, Cancer Res. 51, 4903-4908 (1991).
16. 16. J. ROCA, R. ISHIDA, J.M. BERGER, T. ANDOH and J. C. WANG, Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp, Proc. Natl Acad. Sci. USA 91, 1781-1785 (1994).
17. 17. P. B. JENSEN, B. S. SORENSEN, M. SEHESTED, E. J. DEMANT, E. KJELDSEN, E. FRICHE and H. H. HANSEN, Different modes of anthracycline interaction with topoisomerase II: separate structures critical for DNA-cleavage, and for overcoming topoisomerase II-related drug resistance, Biochem. Pharmacol. 45, 2025-2035 (1993).
18. 18. M. CHEN and W. T. BECK, Teniposide-resistant CEM cells, which express mutant DNA topoisomerase IIα, when treated with non-complex-stabilizing inhibitors of the enzyme, display no cross-resistance and reveal aberrant functions of the mutant enzyme, Cancer Res. 53, 5946-5953 (1993).
19. 19. M. SEHESTED and P. B. JENSEN, Mapping of DNA topoisomerase II poisons (etoposide, clerocidin) and catalytic inhibitors (aclarubicin, ICRF-187) to four distinct steps in the topoisomerase II catalytic cycle, Biochem. Pharmacol. 51, 879-886 (1996).
20. 20. H. ZHANG, P. D'ARPA and L. F. LIU. A model for tumor cell killing by topoisomerase poisons, Cancer Cells 2, 23-27 (1990).
21. 21. S. J. FROELICH-AMMON and N. OSHEROFF, Topoisomerase poisons: harnessing the dark side of enzyme mechanism, J. Biol. Chem. 270, 21429-21432 (1996).
22. 22. J. F. R. KERR, J. SEARLE, B. V. HARMON and C. J. BISHOP, Apoptosis, pp. 93-128 in Perspectives on Mammalian Cell Death (C. S. POTTEN, ed.). Oxford Science, Oxford (1987).
23. 23. J. J. COHEN, Programmed cell death in the immune system, Advan. Immunol. 50, 55-85 (1991).
24. 24. B. J. FOWLKES and D. M. PARDOLL, Molecular and cellular events of T cell development, Advan. Immunol. 44, 207-264 (1989).
25. 25. Y. ONISHI, Y. AZUMA, Y. SATO, Y. MIZUNO, T. TADAKUMA and H. KIZAKI, Topoisomerase inhibitors induce apoptosis in thymocytes, Biochim. Biophys. Acta 1175, 147-154 (1993).
26. 26. X. M. SUN, P. CARTHEW, D. DINSDALE, R. T. SNOWDEN and G. M. COHEN, The involvement of apoptosis in etoposide-induced thymic atrophy, Toxicol. Appl. Pharmacol. 128, 78-85 (1994).
27. 27. S. H. KAUFMANN, Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin, and other cytotoxic anticancer drugs: a cautionary note, Cancer Res. 49, 5870-5878 (1988).
28. 28. N. KYPIANOU, R. B. ALEXANDER and J. T. ISAACS, Activation of programmed cell death by recombinant human tumor necrosis factor plus topoisomerase II targeted drugs in L929 tumor cells, J. Natl. Cancer Inst. 83, 346-350 (1991).
29. 29. T. YAMADA and H. OHYAMA, Radiation-induced interphase death of rat thymocytes is internally programmed (apoptosis), Int. J. Radiat. Biol. 53, 65-75 (1988).
30. 30. H. KIZAKI, T. TADAKUMA, C. ODAKA, J. MURAMATSU and Y. ISHIMURA, Activation of a suicide process of thymocytes through DNA fragmentation by calcium ionophores and phorbol esters, J. Immunol. 143, 1790-1794 (1989).
31. 31. Y. AZUMA, Y. ONISHI, Y. SATO and H. KIZAKI, Effects of protein tyrosine kinase inhibitors with different modes of action on topoisomerase activity and death of IL-2-dependent CTLL-2 cells, J. Biochem. 118, 312-318 (1995).
32. 32. Y. ONISHI, Y. AZUMA and H. KIZAKI, An assay method for DNA topoisomerase activity based on separation of relaxed DNA from supercoiled DNA using high-performance liquid chromatography, Anal. Biochem. 210, 63-68 (1993).
33. 4-3-ketosteroid 5β-reductase of rat liver, FEBS Lett. 283, 215-218 (1991).
34. 34. H. SIVE and T. ST JOHN, A simple subtractive hybridization technique employing photoactivatable biotin and phenol extraction, Nucl. Acids Res. 16, 10937n (1988).
35. 35. M.A. FROHMAN, M.K. DUSH and G.R. MARTIN, Rapid production of full-length cDNAs from rare transcripts: Amplification using a single gene-specific oligonucleotide primer, Proc. Natl Acad. Sci. USA 85, 8998-9002 (1988).
36. 36. A. KRISHAN, Rapid flow cytofluorometric analysis of mammalian cell cycle by propidium iodide staining, J. Cell Biol. 66, 188-193 (1975).
37. 37. H. KIZAKI and Y. ONISHI, Thymocytes apoptosis induced by topoisomerase inhibitors, pp. 347-352 in Current Topics in Mucosal Immunology (M. TSUCHIYA, J. YODOI, T. HIBI and S. MIURA, eds.). Excerpta Medica, Tokyo, Japan (1993).
38. 38. B. T. GJERTSEN and S. O. DØSKELAND, Protein phosphorylation in apoptosis, Biochim. Biophys. Acta 1269, 187-199 (1995).
39. 39. H. KIZAKI and T. TADAKUMA, Thymocyte apoptosis, Microbiol Immunol. 37, 917-925 (1993).
40. 40. B. STRULOVICI, S. DANIEL-ISSAKANI, G. BAXTER, J. KNOPF, L. SULTZMAN, H. CHERWINSKI, J. NESTOR, D. R. WEBB and J. RANSOM, Distinct mechanisms of regulation of PKC ε by hormones and phorbol diesters, J. Biol. Chem. 266, 168-173 (1991).
41. 41. J. M. RUSNAK and J. S. LAZO, Downregulation of protein kinase C suppresses induction of apoptosis in human prostatic carcinoma cells, Exptl Cell Res. 224, 189-199 (1996).
42. 42. Y. ONISHI, Y. AZUMA and H. KIZAKI, Bis (2,6-dioxopiperazine) derivatives, topoisomerase II inhibitors which do not form DNA cleavable complex, induce thymocyte apoptosis, Biochem. Mol. Biol. Int. 32, 115-122 (1994).
43. 43. M. J. ROBERGE, J. TH'NG, J. HAMAGUCHI and E. M. BRADBURY, The topoisomerase II inhibitor VM-26 induces marked changes in histone H1 kinase activity, histones H1 and H3 phosphorylation and chromosome condensation in G2 phase and mitotic BHK cells. J. Cell Biol. 111, 1753-1763 (1990).
44. cdc2 tyrosine dephosphorylation, and mitotic progression in Chinese hamster ovary cells exposed to etoposide, Cancer Res. 52, 1817-1822 (1992).
45. 45. M. CHEN and W. T. BECK, Differences in inhibition of chromosome separation and G2 arrest by DNA topoisomerase II inhibitors merbarone and VM-26, Cancer Res. 55, 1509-1516 (1995).
46. 46. R. ISHIDA, M. SATO, T. NARITA, K. R. UTSUMI, T. NISHIMOTO, T. MORITA, H. NAGATA and T. ANDOH, Inhibition of DNA topoisomerase II by ICRF-193 induces polyploidization by uncoupling chromosome dynamics from other cell cycle events, J. Cell Biol. 126, 1341-1351 (1994).
47. 47. M. BUVOLI, G. BIAMONTI, P. TSOULFAS, M. T. BASSI, A. GHETTI, S. RIVA and C. MORANDI, cDNA cloning of human hgRNP protein A1 reveals the existence of multiple mRNA isoforms, Nucl. Acids Res. 16, 3751-3768 (1988).
48. 48. A. MAYEDA and A. R. KRAINER, Regulation of alternative pre-mRNA splicing by hnRNP A1 and splicing factor SF2, Cell 68, 365-375 (1992).
49. 49. C. G. BURD and G. DREYFUSS, RNA binding specificity of hnRNP A1: significance of hnRNP A1 high-affinity binding sites in pre-mRNA splicing, EMBO J. 13, 1197-1204 (1994).
50. 50. S. W. LOWE, E. M. SCHMITT, S. W. SMITH, B. A. OSBORNE and T. JACKS, p53 is required for radiation-induced apoptosis in mouse thymocytes, Nature 362, 847-849 (1993).
51. 51. A. R. CLARK, C. A. PURDIE, D. J. HARRISON, R. G. MORRIS, C. C. BIRD, M. L. HOOPER and A. H. WYLLIE, Thymocytes apoptosis induced by p53-dependent and independent pathways, Nature 362, 849-852 (1993).